CEL-SCI Partners with Saudi Amarox to Commercialize Multikine Immunotherapy

Key Facts

1CEL-SCI and Saudi Amarox will hold a signing ceremony at BIO 2026 for a strategic agreement to advance the commercialization and distribution of Multikine in Saudi Arabia.

In a move reflecting the growing expansion of global biotech firms into Gulf markets, CEL-SCI Corporation has announced a strategic agreement with Saudi Amarox. According to reports, a formal signing ceremony will be held at the BIO 2026 convention to advance the commercialization and distribution of Multikine, an investigational immunotherapy for head and neck cancer, within Saudi Arabia.

This partnership comes as healthcare investments in Saudi Arabia see significant growth, with Amarox aiming to leverage its robust local distribution network to introduce CEL-SCI’s advanced therapies. Compared to sector peers, this collaboration focuses on addressing gaps in advanced oncology treatments, aligning with the Kingdom's goals to localize pharmaceutical industries per market data.

Investors are monitoring the performance of CVM stock, currently trading on US exchanges, as this move bolsters the company's prospects for future regulatory approvals in the region. Looking at the economic calendar, traders are awaiting OPEC meeting outcomes and their impact on regional market liquidity, while focusing on the stock's current levels as of the June 11, 2026 close.